An Open-Label, Crossover Study to Assess the Effect of Food on the Oral Bioavailability and Pharmacokinetic Profile of 3'-Deoxy-3'-Fluorothymidine (FLT) in Asymptomatic Human Immunodeficiency Virus (HIV)-Infected Subjects

Inclusion Criteria Patients must have: * Positive ELISA test confirmed by Western blot analysis. * Asymptomatic. * Willing to sign an informed consent. Exclusion Criteria Co-existing Condition: Patients with the following conditions or symptoms are excluded: * Oral candida infection documented by morphology or by a response to antifungal therapy within two months prior to study entry. * Oral hairy leukoplakia at any time prior to entry. * Temperature \> 37.8 C. * Any malignancy other than cutaneous basal cell carcinoma or cervical carcinoma in situ. * Significant chronic underlying medical illness which would prevent continuous participation in this clinical trial. * Unwilling to sign an informed consent. * Zidovudine induced hematological toxicity. Prior Medication: Excluded: * Therapy with antiretroviral drugs or immunomodulators within seven days before entry. * Therapy with any investigational drug during the preceding 30 days. Patients may not have: * Oral candida infection documented by morphology or by a response to antifungal therapy within two months prior to study entry. * Oral hairy leukoplakia at any time prior to entry. * Temperature \> 37.8 C. * Any malignancy other than cutaneous basal cell carcinoma or cervical carcinoma in situ. * Significant chronic underlying medical illness which would prevent continuous participation in this clinical trial. * Unwilling to sign an informed consent. * Zidovudine induced hematological toxicity.